Excellent therapeutic response to pembrolizumab in a 51-year-old patient with metastatic urothelial carcinoma

Czech version

Authors: Barbora Bošanská ¹; Gabriel Varga ^1,2; Michal Eid- ^{2 4}; Dávid Said ^2,5; Michal Fedorko ^1,2
Authors‘ workplace: Urologická klinika FN Brno 2 LF MU, Brno 3 Interní hematologická, a onkologická klinika FN Brno 4 Centrum precizní medicíny, FN Brno 5 Ústav patologie, FN Brno ¹
Published in: Ces Urol 2025; 29(1): 38-42
Category: Case report
doi: https://doi.org/10.48095/cccu2025008

Overview

This article provides a comprehensive overview of the therapeutic options for generalized urothelial carcinoma. The course of treatment is demonstrated by a model case report. Recommendations and treatment effect are supported by recent clinical trial results and in accordance with the latest recommendations of the European Urological Association.

The authors present a case report of a patient suffered from metastatic urothelial carcinoma and discuss the role and efficacy of pembrolizumab in the context of comprehensive genomic profiling of tumor tissue.

Keywords:

imunotherapy, pembrolizumab, next-generation sequencing, urothelial carcinoma

Sources

1. Witjes JA, Bruins HM, Carrión A et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer. In: EAU Guidelines. Presented at the EAU Annual Congress Paris 2024, Arnhem, The Netherlands: EAU Guidelines Office 2024; 7– 62.

2. Linares Espinós E, Santiago I et al. Urology: the last review 2024. Edition 2024. Berlin, Germany: Knowuro 2024; 176– 187.

3. Powles T, Bellmunt J, Comperat E et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis and treatment and follow-up. Ann Oncol 2022; 33(3): 244– 258. doi: 10.1016/ j.annonc.2021.11.012.

4. Yu SH, Kim SS, Kim S et al. FGFR3 mutations in urothelial carcinoma: a single-center study using next-generation sequencing. J Clin Med 2024, 13(5): 1305. doi: 10.3390/ jcm13051305.

5. Voutsadakis IA. Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr Oncol 2022; 29(3): 1390– 1407. doi: 10.3390/ curroncol29030117.

6. Palmeri M, Mehnert J, Silk AW et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers, ESMO Open 2022; 7(1): 100336. doi: 10.1016/ j.esmoop.2021.100336.

7. Powles T, Valderrama BP, Gupta S et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024; 390(10): 875– 888. doi: 10.1056/ NEJMoa2312117.

8. Ascione CM, Napolitano F, Esposito D et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev 2023; 115: 102530. doi: 10.1016/ j.ctrv.2023.102530.

9. Balar AV, Castellano DE, Grivas P et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of followup. Ann Oncol 2023; 34(3): 289– 299. doi: 10.1016/ j.annonc.2022.11.012.

10. Bellmunt J et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl J Med 2017; 376: 1015– 1026. doi: 10.1056/ NEJMoa1613683.